News for 'life-sciences'

Nirma to tap into own funds, debt to buy Glenmark Life Sciences

Nirma to tap into own funds, debt to buy Glenmark Life Sciences

Rediff.com25 Sep 2023

Nirma has roped in BCG and KPMG to advise it on the fundraising options for the acquisition. The company had earlier informed banks that it would raise Rs 5,000 crore to Rs 7,000 crore in the current financial year for the acquisition. Bankers said the company will rely on its funds and future GLS dividend to repay its debt for acquisition.

HCLTech profit flat at Rs 4,235 cr, revenue rises 10.7% in Q2FY26

HCLTech profit flat at Rs 4,235 cr, revenue rises 10.7% in Q2FY26

Rediff.com14 Oct 2025

HCLTech reported flat net income of Rs 4,235 crore in the second quarter of 2025-26 (Q2FY26) compared to last year, even as its revenue was up 10.7 per cent to Rs 31,492 crore helped by financial services and technology business verticals.

Deepinder Goyal's $25 Mn Bet On Longer Life

Deepinder Goyal's $25 Mn Bet On Longer Life

Rediff.com3 Nov 2025

'Our goal here is to become a small catalyst in humanity's journey of conscious evolution. To lead us into the Post-Darwin era.'

Persistent's premium valuations hinge on sustaining growth momentum

Persistent's premium valuations hinge on sustaining growth momentum

Rediff.com29 Oct 2025

The stock of mid-tier information technology (IT) major Persistent Systems has been one of the outperformers in the IT pack with a return of 5.3 per cent over the last year, while its peer index, the Nifty IT, is down 16.2 per cent over the same period. The strong September quarter (Q2FY26) result and upgrades by brokerages are positive but its ability to sustain growth momentum in a weak macroeconomic environment will be key for future gains. At the current levels, the stock is trading at a premium valuation of 38 times its FY27 earnings estimates.

Physical AI: The Next Big Leap in Manufacturing

Physical AI: The Next Big Leap in Manufacturing

Rediff.com18 Oct 2025

Physical AI equips machines with the ability to perceive, learn, and act in the real world by integrating AI algorithms with sensors and actuators in physical systems like robots and vehicles.

Infosys Q2 profit up 13% to Rs 7,364 crore

Infosys Q2 profit up 13% to Rs 7,364 crore

Rediff.com17 Oct 2025

IT company Infosys on Thursday posted 13.2 per cent increase in consolidated net profit at Rs 7,364 crore for the second quarter ended September 30, 2025.

Which city has highest area under office lease?

Which city has highest area under office lease?

Rediff.com19 Oct 2025

Colliers reports that GCC leasing has jumped from 4.6 million square feet in 2021 and is expected to hit 10.6 million square feet by 2025 -- a clear sign that multinationals see Bengaluru as a long-term base.

VHB Life Sciences plans IPO

VHB Life Sciences plans IPO

Rediff.com5 Jun 2007

The six-decade-old pharmaceutical company VHB Life Sciences will come out with an initial public offer in July this year to fund its Rs 400-crore

Pharma M&As to drive Infosys' life sciences biz

Pharma M&As to drive Infosys' life sciences biz

Rediff.com5 Jun 2014

Launches cloud-based version of solution to target mid-size clients in life sciences.

How Vibe Coding is Redefining IT Hiring

How Vibe Coding is Redefining IT Hiring

Rediff.com2 Sep 2025

People with no knowledge of coding or computer languages can use vibe coding using plain English command with AI-assisted software development.

Shuks leads pivotal muscle-loss study aboard ISS

Shuks leads pivotal muscle-loss study aboard ISS

Rediff.com1 Jul 2025

Group Captain Shubhanshu Shukla, the first Indian astronaut at the International Space Station (ISS), conducted a critical biomedical experiment aboard the ISS on flight day 6 of the Axiom 4 Mission, focusing on how microgravity contributes to muscle loss.

Life sciences: India at No.2 behind China

Life sciences: India at No.2 behind China

Rediff.com7 Jul 2010

The combined revenues of Indian life sciences companies was $21 billion taking India to the number two spot behind China.

US drug regulator warns RPG Life Sciences

US drug regulator warns RPG Life Sciences

Rediff.com19 Jun 2013

The US Food and Drug Administration (USFDA) has issued a warning letter to RPG Life Sciences for violation of current good manufacturing practice (CGMP) norms at its two plants at Ankleshwar and Mumbai.

How To Get Hired By India's $68 Bn GCCs

How To Get Hired By India's $68 Bn GCCs

Rediff.com17 Sep 2025

'Employers increasingly want candidates who can take AI pilots from proof-of-concept to production-ready systems.' 'That requires governance, monitoring, and ROI measurement -- skills that go beyond coding and into business impact.'

Reliance Life Sciences ties up with US co

Reliance Life Sciences ties up with US co

Rediff.com26 Apr 2007

Adding a new dimension to its business, the Mukesh Ambani-led Reliance Life Sciences announced on Thursday its partnership with US-based global investment management firm, MPM Capital LP.

250,000 AI 'Experts' At India's IT Firms

250,000 AI 'Experts' At India's IT Firms

Rediff.com30 Jul 2025

'Advanced skills is such a broad spectrum that a simple prompt engineer to a critical upper end LLM developer are clubbed under one.' 'In addition, some include their non-technical employees who can use AI tools under this talent base.'

Why Gen Z Fears AI And Big Tech Jobs

Why Gen Z Fears AI And Big Tech Jobs

Rediff.com8 Aug 2025

Gen Z, driven by AI anxiety and economic pragmatism, have concerns about pursuing passions as careers as they fear it may not make them enough sufficient income.

Gaganyaan To Head To Space In Early 2027

Gaganyaan To Head To Space In Early 2027

Rediff.com25 Aug 2025

The Human-rated LVM3 vehicle, the Crew Escape System and the Crew Module and Service Module are all in final stages of testing and integration.

'The Nature Of Jobs Will Change'

'The Nature Of Jobs Will Change'

Rediff.com22 Jul 2025

'This is the time to be creative, use AI in real-time operations, and unlock new demand and aspirations.'

What Shux Did In His 1st Week In Space

What Shux Did In His 1st Week In Space

Rediff.com10 Jul 2025

Shubhanshu Shukla's first seven days in space have combined science, ceremony, and moments of levity.

Shuks eyes Gaganyaan after historic ISS mission

Shuks eyes Gaganyaan after historic ISS mission

Rediff.com15 Jul 2025

Astronaut Shubhanshu Shukla returns to Earth after an 18-day mission aboard the International Space Station, marking a significant milestone for India's space program and carrying out crucial scientific experiments.

Mid-tier IT firms outpaced larger peers' growth in FY25

Mid-tier IT firms outpaced larger peers' growth in FY25

Rediff.com22 May 2025

Mid-tier information-technology (IT) companies last financial year reported better growth numbers than their larger counterparts, highlighting their ability to navigate the uncertain macroeconomic environment. Most of these companies - such as Persistent Systems, Coforge, KPIT, and Mphasis - focus on niche businesses and industries that allow them to go deeper in terms of client mining and expanding wallet share from existing customers.

Want To Study BPharm, Engineering In Europe?

Want To Study BPharm, Engineering In Europe?

Rediff.com11 Jul 2025

rediffGURU Sushil Sukhwani offers guidance about the best courses and colleges for an international education.

Mutual Funds Emerge As Financiers For M&A Deals

Mutual Funds Emerge As Financiers For M&A Deals

Rediff.com6 Feb 2025

'Growth for some companies has been hard to come by and this is a smart way to get there.'

'Medicines are just one part of the solution'

'Medicines are just one part of the solution'

Rediff.com21 May 2025

'We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a particular disease area globally.'

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Rediff.com23 Dec 2024

India's healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According to data, key contributors to the record fundraising included Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore).

Five main-board, 6 SMEs to hit the markets to raise Rs 18,500 cr

Five main-board, 6 SMEs to hit the markets to raise Rs 18,500 cr

Rediff.com8 Dec 2024

The IPO market is set to be bustling next week, with 11 companies like Vishal Mega Mart, TPG Capital-backed Sai Life Sciences and fintech firm One Mobikwik Systems gearing up to launch their initial share sales, collectively aiming to raise nearly Rs 18,500 crore. Other mainboard IPOs to be launched during this period are Inventurus Knowledge Solutions Ltd and Blackstone-owned diamond grading firm International Gemmological Institute (India) Ltd.

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

Rediff.com14 May 2025

A fresh US executive order (EO) which seeks to bring down prices of prescription drugs in the country by up to 90 per cent -- on par with other developed nations -- will affect innovator companies, while sparing the Indian generic drug makers in the short term. US President Donald Trump signed the EO on Monday, directing the US Trade Representative and the Secretary of Commerce to act against foreign countries that "purposefully and unfairly undercut market prices", driving price hikes in the US.

'Lost 6 Years Preparing For NEET. Can I Do MBA Now?'

'Lost 6 Years Preparing For NEET. Can I Do MBA Now?'

Rediff.com7 May 2025

rediffGURU Dr Nagarajan JSK helps students make the right career choices.

Growth jitters take a 'byte' out of TCS

Growth jitters take a 'byte' out of TCS

Rediff.com27 Feb 2025

Shares of Tata Consultancy Services (TCS), the country's largest IT services provider, continue to remain under pressure, hitting a new eight-month low of Rs 3,624.90 intraday on Tuesday before closing at Rs 3,631, down 1.19 per cent. In the past two trading sessions, the stock price has declined 4 per cent on fears of a slowing US economy.

Budget 2025: Grassroot Level Implementation Is Necessary

Budget 2025: Grassroot Level Implementation Is Necessary

Rediff.com5 Feb 2025

Simplifying investment policies at the micro level and introducing a time-bound framework will be critical for India's growth targets, notes Krishna Ella.

Mobikwik leads IPO debut with 90% surge; Vishal, Sai Life gain around 40%

Mobikwik leads IPO debut with 90% surge; Vishal, Sai Life gain around 40%

Rediff.com19 Dec 2024

All the three companies that made their stock market debut on Wednesday delivered huge day-one gains for investors. Shares of digital payment major One Mobikwik Systems surged 90 per cent, while that of fashion retailer Vishal Mega Mart and pharma firm Sai Life Sciences gained around 40 per cent each. These stellar debuts came despite the benchmark indices logging continuous declines since their initial public offerings (IPOs) closed on Friday.

Reliance spent $13 bn on acquisitions in five years

Reliance spent $13 bn on acquisitions in five years

Rediff.com31 Dec 2024

Billionaire Mukesh Ambani's Reliance Industries Ltd has spent $13 billion on acquisitions in the past five years across new energy, telecom, retail and media business to script a pivot away from core oil and petrochemicals business to clean energy and consumer facing verticals. Last week, Reliance bought oncology platform Karkinos Healthcare for Rs 375 crore, adding another stack to its diagnostic and digital healthcare ecosystem, Morgan Stanley said in a report.

Institutional investment in real estate jumps 31% to $1.3bn

Institutional investment in real estate jumps 31% to $1.3bn

Rediff.com5 Apr 2025

The growth was primarily driven by domestic investments, which accounted for 60 per cent of the total inflows during the first quarter of the financial year.

Investors return to IPOs with Rs 2.2 trillion bids across three offerings

Investors return to IPOs with Rs 2.2 trillion bids across three offerings

Rediff.com14 Dec 2024

It is not just the secondary market that is witnessing a revival in fortunes. Even the initial public offering (IPO) market have roared back to life, with investors submitting bids worth over Rs 2.2 trillion on the three IPOs that wrapped up on Friday. Fashion retailer Vishal Mega Mart (VMM)'s IPO (fifth largest of the year) garnered 27.3x subscription, with bids exceeding Rs 1.6 trillion.

US sanctions 15 Indian entities for backing Russia

US sanctions 15 Indian entities for backing Russia

Rediff.com1 Nov 2024

The United States has imposed sanctions on 275 individuals and entities, including 15 from India, for allegedly supporting Russia's military-industrial base.

IPO pipeline: 10 companies aim to raise Rs 20,000 cr in Dec

IPO pipeline: 10 companies aim to raise Rs 20,000 cr in Dec

Rediff.com24 Nov 2024

The primary market is expected to remain vibrant, with at least 10 companies, including supermart major Vishal Mega Mart and Blackstone-owned diamond grading firm International Gemmological Institute (India) Ltd expected to raise a combined Rs 20,000 crore in the next month, merchant bankers said. Education-focused NBFC Avanse Financial Services, TPG Capital-backed Sai Life Sciences, hospital chain operator Paras Healthcare, and investment bank DAM Capital Advisors are also among the companies planning to launch their IPOs in December, they added. The companies aim to raise a total of Rs 20,000 crore through their public offerings.

Techies, Want A Job At Marlabs?

Techies, Want A Job At Marlabs?

Rediff.com5 Mar 2024

'The hiring in India will be primarily around skills in data engineering, AI, and product engineering.'

NTA postpones June edition of joint CSIR-UGC-NET exam

NTA postpones June edition of joint CSIR-UGC-NET exam

Rediff.com22 Jun 2024

The postponement comes two days after the National Testing Agency cancelled the UGC-NET examination within 24 hours of its conduct, saying the integrity of the exam had been compromised.